Welcome to our dedicated page for Actinium Pharmac news (Ticker: ATNM), a resource for investors and traders seeking the latest updates and insights on Actinium Pharmac stock.
The Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) news page on Stock Titan aggregates company announcements, scientific conference updates and regulatory disclosures related to its Actinium-225 targeted radiotherapy programs. Actinium regularly issues press releases detailing preclinical and clinical data, corporate events and participation in oncology meetings, offering investors and observers insight into the evolution of its pipeline.
Recent news has focused heavily on ATNM-400, the company’s first-in-class, multi-indication Ac-225 antibody radioconjugate. Actinium has reported preclinical data for ATNM-400 in metastatic castration-resistant prostate cancer, non-small cell lung cancer (NSCLC) and breast cancer, including models resistant to standard-of-care therapies such as enzalutamide, 177Lu-PSMA-617, osimertinib, tamoxifen and trastuzumab. Releases describe superior tumor growth inhibition versus several approved agents, durable tumor control, and synergistic effects when ATNM-400 is combined with ARPIs or EGFR inhibitors.
News items also cover Actimab-A, a CD33-targeting Ac-225 therapeutic for acute myeloid leukemia, including its planned pivotal Phase 2/3 trial and a Cooperative Research and Development Agreement with the National Cancer Institute. Additional updates describe Iomab-ACT and Iomab-B in conditioning for bone marrow transplant and cell or gene therapies, as well as Actinium’s broader research efforts in solid tumors.
Visitors to this page can review earnings‑independent scientific updates, conference abstracts and corporate communications that outline Actinium’s development strategy, preclinical results and governance milestones such as annual meeting outcomes. For anyone tracking ATNM as an oncology development story, this news feed provides a centralized view of how the company portrays progress across its Ac‑225 radiotherapy platform.
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) has priced its public offering of 76,923,077 shares at $0.325 per share, expecting gross proceeds of approximately $25 million. The offering is set to close around June 19, 2020. The net proceeds will fund the ongoing Phase 3 SIERRA trial for its product candidate Iomab-B, preparations for a Biologics License Application (BLA), and other developmental initiatives, including Phase 1 trials and general working capital. H.C. Wainwright & Co. is the exclusive placement agent for the offering.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) announced a proposed public offering of its common stock, subject to market conditions. The company plans to utilize the net proceeds from the offering to advance its pivotal Phase 3 SIERRA trial for Iomab-B, prepare a Biologics License Application to the FDA, and support commercialization efforts. Additionally, funds will be allocated to Phase 1 trials for its CD33 program, research and development, and general working capital. H.C. Wainwright & Co. is the exclusive placement agent for this offering.